Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 3/20 | 0.55 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | SNCA | P37840 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13080589 | 0.81 | LRRK2 (0.61) | PDGFRBRETTGM2 | |
| SCHEMBL7138968 | 0.81 | MAPT (0.49) | GSK3BPDGFRBRETMEN1KMT2A | |
| SCHEMBL1388393 | 0.81 | PDPK1 (0.54) | GSK3BPDGFRBRETMEN1KMT2A | |
| SCHEMBL1388519 | 0.81 | RET (0.54) | GSK3BPDGFRBRETMEN1KMT2A | |
| SCHEMBL13080586 | 0.81 | FLT3 (0.56) | PDGFRBMEN1KMT2ACCNE1CDK2 | |
| SCHEMBL7874137 | 0.81 | GSK3B (0.59) | GSK3BPDGFRBJAK3RETMEN1 | |
| SCHEMBL8291555 | 0.81 | GSK3B (0.59) | GSK3BPDGFRBJAK3RETMEN1 | |
| SCHEMBL1388800 | 0.79 | TLK2 (0.57) | PDGFRBJAK3MEN1KMT2ACDK2 | |
| SCHEMBL31219496 | 0.78 | GSK3B (0.74) | GSK3BPDGFRBJAK3RETNOX4 | |
| SCHEMBL3757263 | 0.78 | GSK3B (0.74) | GSK3BPDGFRBJAK3RETNOX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | GSK3B 69/4885PDGFRB 2159/4885JAK3 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.